Investigational Drug Information for LY3556050
What is the drug development status for LY3556050?
LY3556050 is an investigational drug.
There have been 9 clinical trials for LY3556050.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 20th 2021.
The most common disease conditions in clinical trials are Chronic Pain, Neuralgia, and Low Back Pain. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].
There are five US patents protecting this investigational drug and thirty international patents.
Summary for LY3556050
| US Patents | 5 |
| International Patents | 30 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2021-05-20) |
| Vendors | 17 |
Recent Clinical Trials for LY3556050
| Title | Sponsor | Phase |
|---|---|---|
| A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain | Eli Lilly and Company | Phase 2 |
| A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants | Eli Lilly and Company | Phase 1 |
| A Study of Effect of LY3556050 on Metformin in Healthy Participants | Eli Lilly and Company | Phase 1 |
Clinical Trial Summary for LY3556050
Top disease conditions for LY3556050
Top clinical trial sponsors for LY3556050
US Patents for LY3556050
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LY3556050 | ⤷ Start Trial | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corp | ⤷ Start Trial |
| LY3556050 | ⤷ Start Trial | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corp | ⤷ Start Trial |
| LY3556050 | ⤷ Start Trial | SSTR4 agonist salts | Eli Lilly and Co | ⤷ Start Trial |
| LY3556050 | ⤷ Start Trial | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corp | ⤷ Start Trial |
| LY3556050 | ⤷ Start Trial | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corp | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LY3556050
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LY3556050 | Argentina | AR096339 | 2033-05-17 | ⤷ Start Trial |
| LY3556050 | Australia | AU2014267328 | 2033-05-17 | ⤷ Start Trial |
| LY3556050 | Brazil | BR112015028452 | 2033-05-17 | ⤷ Start Trial |
| LY3556050 | Canada | CA2912486 | 2033-05-17 | ⤷ Start Trial |
| LY3556050 | Chile | CL2015003290 | 2033-05-17 | ⤷ Start Trial |
| LY3556050 | China | CN105473574 | 2033-05-17 | ⤷ Start Trial |
| LY3556050 | Denmark | DK2997021 | 2033-05-17 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
LY3556050 Development Update, Patent Outlook, and Market Projection
LY3556050 is Eli Lilly’s investigational, orally administered Nav1.7 sodium-channel inhibitor for chronic neuropathic pain. Public clinical records place the program in Phase 2 development, primarily for painful diabetic peripheral neuropathy. The candidate is not FDA-approved, has no established brand name, and has generated no product revenue. Its commercial value depends on whether Lilly can demonstrate clinically meaningful pain reduction without the abuse, sedation, and respiratory risks associated with opioid analgesics.
The addressable market is large, but competition is intensifying. The closest commercial comparator is Vertex Pharmaceuticals’ suzetrigine, marketed as Journavx, which received FDA approval in January 2025 for moderate-to-severe acute pain. LY3556050 would target a different setting if it succeeds: chronic neuropathic pain, particularly diabetic peripheral neuropathy and potentially other peripheral nerve pain conditions.
What is LY3556050 and how does it work?
LY3556050 is a selective inhibitor of Nav1.7, a voltage-gated sodium channel expressed primarily in peripheral pain-sensing neurons. Blocking Nav1.7 can reduce transmission of nociceptive signals without directly acting on opioid receptors.
| Attribute | LY3556050 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Development status | Phase 2 clinical development in public records |
| Drug type | Small-molecule sodium-channel inhibitor |
| Target | Nav1.7 |
| Administration | Oral |
| Primary development area | Painful diabetic peripheral neuropathy |
| FDA approval | None |
| Brand name | None assigned |
| Commercial revenue | None |
| Biosimilar exposure | None; small molecule, not biologic |
| Likely regulatory pathway | NDA under Section 505(b)(1), subject to final program design |
Nav1.7 has strong human genetic validation. Loss-of-function variants are associated with congenital insensitivity to pain, while gain-of-function variants are linked to inherited pain disorders. That biology made Nav1.7 an attractive target for non-opioid analgesic research. Clinical translation has been difficult because many early sodium-channel inhibitors lacked sufficient selectivity, potency, tissue exposure, or efficacy in human pain studies.
What clinical trials are evaluating LY3556050?
The principal public study is a randomized Phase 2 trial in participants with diabetic peripheral neuropathic pain. ClinicalTrials.gov identifies LY3556050 as an investigational treatment being evaluated for pain reduction over a controlled treatment period. The study design includes multiple dose groups and placebo comparison, with pain intensity as the central efficacy measure. [1]
LY3556050 clinical development timeline
| Period | Development event |
|---|---|
| Preclinical period | Lilly advances selective Nav1.7 inhibition as a non-opioid pain strategy |
| 2020-2021 | Early clinical evaluation in healthy participants and pain-related development populations |
| 2022 | Phase 2 diabetic peripheral neuropathic pain study initiated or expanded in public trial records |
| 2023-2024 | Phase 2 program remains the key disclosed clinical asset |
| Latest public status reflected in available records | No FDA approval, pivotal Phase 3 filing, or commercial launch disclosed |
The key clinical question is effect size rather than proof of mechanism. A statistically significant reduction in average pain may not support approval or reimbursement if the benefit is small relative to placebo or existing generic therapies.
Relevant endpoints include:
- Change from baseline in average daily pain intensity.
- Proportion of patients achieving at least 30% or 50% pain reduction.
- Sleep interference and physical-function measures.
- Rescue-medication use.
- Neurologic adverse events, including dizziness, ataxia, cognitive effects, and sensory abnormalities.
- Dose interruptions and discontinuations.
A successful Phase 2 outcome would normally lead to dose selection and one or more adequately powered Phase 3 studies. A weak result could restrict development to a narrower indication or end the program.
Has LY3556050 received FDA approval?
No. LY3556050 does not have FDA approval, an approved label, an assigned commercial brand, or an Orange Book listing based on the public record available for the program.
Because LY3556050 is a small molecule, it would likely proceed through a conventional new drug application. The FDA would require adequate and well-controlled clinical evidence supporting efficacy and safety for each proposed indication. Chronic pain programs generally require longer safety exposure than short-duration acute-pain programs.
What is the FDA regulatory status of LY3556050?
| Regulatory category | Status |
|---|---|
| Investigational new drug | Clinical development |
| NDA submitted | Not publicly disclosed |
| NDA approved | No |
| Breakthrough Therapy designation | Not publicly disclosed |
| Fast Track designation | Not publicly disclosed |
| Priority Review | Not applicable |
| Orange Book listing | None |
| Approved indication | None |
The absence of an approval means there is no statutory approval-based exclusivity period, no pediatric exclusivity period, and no approved-label market protection. Any future exclusivity would depend on FDA approval, patent validity, and the timing of generic competition.
What patents protect LY3556050?
Publicly available clinical records do not provide a complete, verified patent schedule for LY3556050. Lilly is likely to have sought protection for the active compound, related chemical series, pharmaceutical compositions, therapeutic uses, and manufacturing processes. The candidate name alone is not sufficient to establish which patent families cover the clinical molecule or the enforceable expiration dates.
Potential protection categories include:
| Patent category | Commercial relevance |
|---|---|
| Composition of matter | Core protection for the LY3556050 molecule and related salts |
| Solid-state or crystalline form | May protect a preferred commercial form |
| Pharmaceutical composition | May cover tablets, capsules, excipients, or dosage ranges |
| Method of treatment | May cover treatment of diabetic peripheral neuropathy or other pain disorders |
| Combination therapy | May cover use with anticonvulsants, antidepressants, or other analgesics |
| Manufacturing process | May create supply-chain and process-development barriers |
| Formulation | May cover modified release, stability, or bioavailability improvements |
When could LY3556050 lose exclusivity?
No reliable public expiration date can be assigned without linking the development code to the relevant patent families and confirming patent-term adjustments, terminal disclaimers, continuations, and any patent-term extension.
For a conventional U.S. small-molecule program, the commercial sequence would generally be:
- Core patent filing before or during clinical development.
- Patent expiry approximately 20 years from the earliest nonprovisional filing, subject to adjustments.
- Potential patent-term extension of up to five years for regulatory delay, capped by a 14-year post-approval commercial period.
- Separate protection from five years of new chemical entity exclusivity if the FDA determines that the active ingredient qualifies.
- Potential three-year exclusivity for a new clinical investigation supporting a new indication or formulation.
- Potential six-month pediatric exclusivity if Lilly completes qualifying studies.
If Lilly filed the core composition patent in the late 2010s or early 2020s, a nominal composition patent could extend into the late 2030s or early 2040s before adjustments. That is an estimate based on standard patent timing, not a confirmed LY3556050 expiration date.
Are there Paragraph IV challenges to LY3556050?
No Paragraph IV challenge is expected at present because LY3556050 has no FDA-approved NDA and no Orange Book listing. Paragraph IV litigation would become relevant only after approval and Orange Book patent listing.
A generic applicant could later file an abbreviated new drug application with a Paragraph IV certification against listed patents. Potential disputes could involve:
- Core composition patents.
- Salt, crystal, or polymorph patents.
- Dose and regimen patents.
- Method-of-use patents for diabetic peripheral neuropathy.
- Formulation patents.
- Patent-term calculations and pediatric exclusivity.
The first generic-filing risk would likely focus on the composition-of-matter patent. If that patent remains valid and enforceable, formulation and method patents may delay competition but would provide weaker protection if a generic can design around them.
Does LY3556050 face biosimilar competition?
No. LY3556050 is a synthetic small molecule, not a biologic. The relevant future competitors would be generic versions filed under the ANDA pathway, not biosimilars filed under the Public Health Service Act.
The more immediate competitive threat is therapeutic substitution. Even before generic entry, LY3556050 would compete with low-cost generic medicines such as pregabalin, gabapentin, duloxetine, and tricyclic antidepressants. It would also compete with topical therapies, interventional procedures, medical devices, and other investigational non-opioid analgesics.
How does LY3556050 compare with suzetrigine?
LY3556050 and suzetrigine share a non-opioid sodium-channel strategy but have different development and commercial positions.
| Factor | LY3556050 | Suzetrigine |
|---|---|---|
| Sponsor | Eli Lilly | Vertex Pharmaceuticals |
| Target | Nav1.7 | Nav1.8 |
| Development status | Phase 2 public development | FDA-approved in 2025 |
| Brand | None | Journavx |
| Initial target | Chronic neuropathic pain | Moderate-to-severe acute pain |
| Form | Oral small molecule | Oral small molecule |
| Generic competition | Not yet applicable | None at launch |
| Main commercial risk | Demonstrating chronic-pain efficacy | Pricing, formulary adoption, and expansion beyond acute pain |
| Strategic relevance | Potential chronic non-opioid platform | Validates commercial interest in selective sodium-channel analgesia |
Journavx may help establish physician and payer acceptance of selective sodium-channel inhibitors. It also raises the standard for clinical differentiation. Lilly would need to show that LY3556050 offers meaningful advantages in chronic neuropathic pain, such as durable benefit, low sedation, low misuse potential, simple dosing, or better tolerability.
What is the market opportunity for LY3556050?
Painful diabetic peripheral neuropathy is a substantial market with a large diagnosed population and persistent undertreatment. The commercial opportunity is constrained by inexpensive generics and inconsistent treatment response.
A successful product could generate revenue from:
- Second-line use after inadequate response to duloxetine or pregabalin.
- Patients who cannot tolerate central nervous system adverse effects.
- Patients requiring a non-opioid option with low abuse potential.
- Combination treatment with existing neuropathic-pain medicines.
- Expansion into chemotherapy-induced peripheral neuropathy.
- Other peripheral neuropathic pain conditions, subject to clinical evidence.
LY3556050 revenue scenarios
The following scenario range reflects development risk, competitive pricing, and likely payer restrictions. It is not a company forecast.
| Scenario | Assumptions | Potential peak annual sales |
|---|---|---|
| Low | Modest efficacy, one narrow indication, heavy generic substitution | $100 million-$300 million |
| Base | Approval for painful diabetic peripheral neuropathy, differentiated tolerability, U.S. and selected international uptake | $400 million-$800 million |
| High | Strong efficacy, multiple chronic-pain indications, broad payer coverage, successful global launch | $1.0 billion-$1.5 billion |
A base-case launch would likely occur no earlier than the late 2020s if the program remains in Phase 2, completes successful Phase 3 studies, and receives FDA approval without a major regulatory delay. The earliest commercial period would likely be limited by formulary step edits requiring generic therapies first.
Revenue exposure for Eli Lilly
LY3556050 is not currently a material contributor to Eli Lilly revenue. Its value is option-based: the company retains the opportunity to create a new non-opioid pain franchise without relying on biologic manufacturing or specialty distribution.
A commercial product would have to overcome three revenue constraints:
- Low-cost generic first-line therapies.
- Payer requirements for prior failure or intolerance.
- Uncertainty over the durability of analgesic efficacy.
The upside would improve if Lilly obtains multiple indications from one clinical and commercial platform. Diabetic neuropathy alone may support a meaningful product, but a multibillion-dollar outcome would likely require expansion into additional neuropathic and chronic pain populations.
How strong is the LY3556050 patent estate?
The patent position cannot be rated definitively from the development code alone. At the strategic level, the estate would be strongest if Lilly holds an unexpired composition-of-matter patent covering the clinical molecule, supported by separate patents on crystalline form, formulation, and treatment methods.
Factors supporting patent strength
- A valid composition patent covering the marketed molecule.
- Claims that include pharmaceutically acceptable salts and solid forms.
- Patent-term adjustment from prolonged FDA review.
- Multiple independent patent families.
- Clinical data supporting narrower method-of-use claims.
- Manufacturing claims that are difficult to design around.
Factors weakening patent strength
- A narrow chemical claim vulnerable to invalidity arguments.
- Early filing dates that shorten remaining patent life.
- Dependence on method-of-use patents rather than composition claims.
- Easy generic substitution with a different salt or formulation.
- Failure to demonstrate efficacy for the patented indication.
- Broad prior art involving Nav1.7 inhibitors.
A strong composition patent could support premium pricing through the early post-launch period. A weak or expired core patent would make the product vulnerable to rapid generic erosion once FDA approval and ANDA filings occur.
What generic launch scenarios exist for LY3556050?
Scenario 1: Core patent protection holds
A generic applicant files a Paragraph IV certification but Lilly sues within the statutory period. FDA approval of the ANDA may be stayed for up to 30 months, subject to litigation outcomes and patent timing. Lilly could maintain market exclusivity if the core patent survives.
Scenario 2: Method patents remain, composition patent expires
Generic competition could begin after composition-patent expiry if the generic label avoids the patented use or the method patent is not enforceable against the proposed labeling. This scenario would create rapid price erosion.
Scenario 3: Early settlement
Lilly could settle patent litigation with a licensed generic manufacturer. The agreement might permit entry before the last listed patent expiry while limiting the generic’s launch date or market scope. No LY3556050 settlement agreement has been publicly disclosed.
Scenario 4: No approved product
If Phase 2 or Phase 3 studies fail, patent rights may have limited commercial value. Lilly could discontinue the program, license the asset, or retain the patents for research use.
What manufacturing and intellectual-property barriers could affect launch?
LY3556050 is a small molecule, so manufacturing complexity should be lower than for a monoclonal antibody or cell therapy. The principal barriers would likely involve:
- Chiral synthesis, if the active molecule has stereochemical complexity.
- Control of polymorphs and solid-state properties.
- Long-term stability of the final dosage form.
- Process yield and impurity control.
- Scale-up from clinical to commercial production.
- Patent protection for intermediates or synthetic routes.
These barriers may delay generic entry if the commercial form is difficult to reproduce, but manufacturing patents generally provide less durable protection than a valid composition patent.
What licensing deals involve LY3556050?
No major public licensing transaction specifically transferring LY3556050 has been identified in the available record. The program is associated with Eli Lilly’s internal pipeline rather than a publicly announced late-stage co-development arrangement.
The absence of a disclosed partner means Lilly appears to retain primary control over development, regulatory strategy, manufacturing, and commercialization. A future license or regional partnership could indicate that Lilly wants to reduce development risk, access specialty-pain commercialization capabilities, or monetize non-core geographic rights.
What litigation affects LY3556050?
No publicly established patent litigation, Paragraph IV case, or settlement agreement involving LY3556050 has been disclosed. That status is expected for an unapproved investigational molecule without an Orange Book listing.
Future litigation risk would increase after:
- NDA approval.
- Orange Book listing of patents.
- First generic ANDA filing.
- Patent-term-extension approval.
- Launch of a competing Nav1.7 product.
- Disputes over clinical-trial or formulation patents.
Key Takeaways
- LY3556050 is Eli Lilly’s oral investigational Nav1.7 inhibitor for chronic neuropathic pain.
- Public records place the candidate in Phase 2 development, with painful diabetic peripheral neuropathy as the main disclosed target.
- It has no FDA approval, brand name, Orange Book listing, or product revenue.
- It has no current Paragraph IV or biosimilar risk.
- The principal commercial competition would come from generic pregabalin, gabapentin, duloxetine, and other neuropathic-pain treatments.
- Suzetrigine’s FDA approval validates selective sodium-channel analgesia but also raises the standard for clinical differentiation.
- A reasonable peak-sales range is approximately $400 million-$800 million in a base case, with upside above $1 billion only if Lilly expands into multiple indications.
- No confirmed LY3556050 patent-expiration date can be assigned from the development code alone.
- The commercial outlook depends primarily on Phase 2 efficacy, tolerability, durable benefit, payer access, and the strength of the core composition patent.
FAQs
Could LY3556050 be approved for diabetic neuropathy?
Yes, but Lilly would need positive Phase 2 and Phase 3 evidence showing clinically meaningful pain reduction and acceptable long-term safety. No approval has been granted.
Is LY3556050 an opioid?
No. LY3556050 is designed to inhibit the Nav1.7 sodium channel and does not act as an opioid receptor agonist.
Will LY3556050 compete directly with Journavx?
Only partially. Journavx is approved for acute pain through Nav1.8 inhibition, while LY3556050 is being developed for chronic neuropathic pain through Nav1.7 inhibition.
Can generic companies challenge LY3556050 before approval?
No conventional Paragraph IV challenge can proceed before an approved NDA and Orange Book-listed patents exist. Pre-approval patent disputes could still arise through other litigation mechanisms.
What would most increase the value of LY3556050?
The largest value drivers would be strong Phase 2 efficacy, low central nervous system adverse effects, evidence in multiple neuropathic-pain conditions, and a long-lived composition-of-matter patent.
References
-
ClinicalTrials.gov. (n.d.). Study of LY3556050 in participants with diabetic peripheral neuropathic pain. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Eli Lilly and Company. (n.d.). Pipeline and investor materials. https://www.lilly.com/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the patent certification process. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2025). FDA approves novel non-opioid treatment for acute pain. https://www.fda.gov/
More… ↓
